The investigators will evaluate response rate, progression free survival (PFS), overall survival (OS), and toxicity of azacytidine combined with CAOLD Regimen in relapsed/refractory peripheral t-cell lymphomas.
Age
18–any
Sex
ALL
Healthy volunteers
Not accepted
You may be eligible if
Patients must satisfy all following criteria to be enrolled in the study:
Pathologically confirmed angioimmunoblastic T-cell lymphoma according World Health Organization (WHO) classification;
Patient is ≥ 18 years of age at the time of signing the informed consent form (ICF).
Patient must understand and voluntarily sign an ICF prior to any study-specific assessments/procedures being conducted;
Patient is willing and able to adhere to the study visit schedule and other protocol requirements;
Meet the following lab criteria:
* Absolute Neutrophil Count (ANC) ≥ 1,5 x 10\^9/L (≥ 1 x 10\^9/L if bone marrow (BM) involvement by lymphoma)
* Platelet ≥ 75 x 10\^9/L (≥ 50 x 10\^9/L if BM involvement by lymphoma)
* Hemoglobin ≥ 8 g/dL.
Anticipated life expectancy at least 3 months
You may not be if
Active or uncontrolled infections requiring systemic treatment within 14 days before enrollment;
Any instability of systemic disease, including but not limited to severe cardiac, liver, kidney, or metabolic disease need therapy;
Pregnant or lactating women
Clareo Health | Azacytidine Plus CAOLD Regimen in Relapsed/Refractory Peripheral T-Cell Lymphomas
